Table 3: Activities of melatonin, and alpha lipoic acid on liver oxidative stress indexes of methotrexate-treated rats.


Treatment MDA (nmole/mgprotein) CAT (U/mgprotein) SOD (U/mgprotein) GSH (μmole/mgprotein) GPx (U/mgprotein)

Control 0.36±0.01 bcd 41.6±2.55 bcde 25.4±2.12 bcd 10.4±0.33 bcd 20.8±1.67 bcde
MT 0.34±0.07 bcd 42.1±3.12 bcde 26.1± 1.21 bcd 10.8±0.42 bcd 22.5±2.63 bcde
ALA 0.35±0.09 bcd 42.6±4.41 bcde 25.5±2.54 bcd 10.6±0.I5 bcd 21.6±2.44 bcde
MT+ ALA 0.34±0.04 bcd 43.5±3.00 bcde 28.2±2.00 bcd 12.0±0.42 bcd 22.0±2.45 bcde
MTX 1.97±0.03 acde 12.7±0.45 acde 7.25±0.42 acde 2.42±0.11 acde 6.38±0.40 acde
MT + MTX 0.98±0.08 abde 17.1±1.27 abde 15.1±1.65 abde 5.49±0.15 abde 9.01±1.33 abde
ALA + MTX 0.60±0.02 abce 23.6±1.33 abce 13.4±1.11 abce 5.32±0.66 abce 11.4±0.15 abce
MT+ALA+MTX 0.37±0.05 bcd 32.8±2.19 abcd 24.2±1.43 bcd 9.93±0.32 bcd 16.5±1.63 abcd

MTX: Methotrexate, MT: Melatonin, ALA: Alpha lipoic Acid, n=6, Data are expressed as Mean± SEM, a Difference at p<0.05 when compared to control, b Difference at p<0.05 when compared MTX, c Difference at p<0.05 when compared MT+MTX, d Difference at p<0.05 when compared ALA+MTX, e Difference at p<0.05 when compared MT+ALA+MTX